Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ultragenyx Pharmaceutical Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RARE
Nasdaq
2834
https://www.ultragenyx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ultragenyx Pharmaceutical Inc
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Mar 22nd, 2024 8:00 pm
10 NASDAQ Stocks with Biggest Upside
- Mar 20th, 2024 12:11 pm
Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
- Mar 12th, 2024 9:00 pm
Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
- Mar 11th, 2024 7:00 pm
10 Biotech Stocks with Huge Potential
- Mar 8th, 2024 2:38 pm
Ultragenyx to Participate at Investor Conferences in March
- Feb 27th, 2024 9:30 pm
Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Feb 17th, 2024 1:23 pm
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
- Feb 16th, 2024 3:43 pm
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
- Feb 16th, 2024 3:35 pm
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
- Feb 16th, 2024 12:53 pm
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- Feb 15th, 2024 9:01 pm
15 Best Strong Buy Stocks To Invest In
- Feb 13th, 2024 6:36 pm
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
- Feb 8th, 2024 9:00 pm
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
- Feb 6th, 2024 1:00 pm
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
- Feb 5th, 2024 9:05 pm
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Jan 25th, 2024 9:05 pm
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
- Jan 18th, 2024 7:41 pm
We're Keeping An Eye On Ultragenyx Pharmaceutical's (NASDAQ:RARE) Cash Burn Rate
- Jan 18th, 2024 10:39 am
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
- Jan 9th, 2024 11:20 pm
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
- Jan 8th, 2024 5:18 pm
Scroll